cagrilintide with semaglutide Co-formulation of and Shows Promise Against Diabetes and Obesity cagrilintide 5mg+semaglutide 5mg Cagrilintide /

Liu N, Wu Q, Liu Y, Li J, Ji P, Fu G

E.MizrahiR.MechawarN.BazinetR

Oral GLP-1s (once FDA-approved) are expected to start at $150/month

This is one of the most recognizable and underreported red flags in real patient experience

At FORTE, thats the model on purpose: you see the whole price before anything ships, and you only pay if a clinician actually prescribes

Tirzepatide has received approval for use in patients with T2D following several phase 3 studies testing and demonstrating its marked anti-hyperglycemic efficacy and positive actions on multiple cardiovascular risk factors, associated with an excellent safety profile [2, 3]